Team Startupcity

• FlexifyMe raises twenty crore rupees in pre-Series A funding led by IvyCap Ventures.
• Plans to expand hybrid care centers, launch posture and gait analysis labs, and boost clinical research.
• Provides AI-powered physiotherapy with live sessions, guided programs, and enterprise healthcare collaborations.

Pune-headquartered healthtech venture FlexifyMe has raised twenty crore rupees from a pre-Series A round led  IvyCap Ventures, with Signal Ventures and current investors joining in on the action.

The new money will go towards speeding up the hybrid care growth of the startup through both online and offline clinics, build advanced posture and gait analysis labs, and boost clinical research partnerships.

Established in 2021, Amit Bhayani and Manjeet Singh, FlexifyMe offers AI-powered physiotherapy solutions for chronic musculoskeletal pain disorders such as neck, lower back, and shoulder afflictions. Leveraging posture and motion analysis technology, its patented system analyzes patient strength and weakness points before bringing them in touch with licensed physiotherapists.

Also Read- Cleantech Startup QuantE Energy Secures $500,000 to Expand Residential Solar Solutions

By integrating AI-powered insights with professional consultations, FlexifyMe departs from symptom-based subjective treatment towards data-based, measurable interventions. FlexifyMe provides live one-to-one physiotherapy sessions, video-guided programs, and online yoga classes on a subscription basis. FlexifyMe also collaborates with business entities, insurers, and health ecosystems to provide clinically proven outcomes.

"By integrating technology, licensed physiotherapists, and aggressive progress monitoring, we are making the path to a pain-free life scientific, objective, and measurable. With this funding, we can scale these strengths so millions avoid unnecessary surgeries, get back to what they love, and achieve meaningful quality of life," said Manjeet Singh, co-founder of FlexifyMe.

FlexifyMe gained popularity after appearing on Shark Tank India Season 3, where it secured a deal with Emcure Pharmaceuticals' executive director Namita Thapar. The startup had earlier raised one million dollars in a seed round, led by Flipkart Ventures.